Unión Europea - español - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - granisetrón - vomiting; cancer - los antieméticos y antinauseants, , serotonina (5ht3) antagonistas de los - prevención de náuseas y vómitos en pacientes que reciben quimioterapia moderadamente o altamente emetógena, con cisplatino o sin este, por hasta cinco días consecutivos. sancuso puede ser utilizado en pacientes que reciben su primer régimen de quimioterapia o en pacientes que han recibido previamente quimioterapia.

Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infecciones por vih - antivirales para uso sistémico - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international n.v. - darunavir, cobicistat - infecciones por vih - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta, está indicado en combinación con otros medicamentos antirretrovirales para el tratamiento de la infección por el virus de la inmunodeficiencia humana 1 (vih 1) en adultos de 18 años o más. el análisis genotípico deben guiar el uso de rezolsta.

Unión Europea - español - EMA (European Medicines Agency)

merck sharp & dohme b.v. - fosfato de tedizolid - soft tissue infections; skin diseases, bacterial - antibacterials for systemic use, , other antibacterials - sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and adolescents 12 years of age and older.

Unión Europea - español - EMA (European Medicines Agency)

sanofi b.v. - tirotropina alfa - neoplasias tiroideas - de la pituitaria anterior del lóbulo hormonas y análogos, la hipófisis y del hipotálamo hormonas y análogos - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Unión Europea - español - EMA (European Medicines Agency)

merck sharp & dohme b.v. - elbasvir, grazoprevir - hepatitis c, crónica - direct acting antivirals, antivirals for systemic use, antivirals for treatment of hcv infections - zepatier is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4. 2, 4. 4 y 5. para el virus de la hepatitis c (vhc) de genotipo específico de la actividad véanse las secciones 4. 4 y 5.

Unión Europea - español - EMA (European Medicines Agency)

pfizer europe ma eeig - voriconazol - candidiasis; mycoses; aspergillosis - antimicóticos para uso sistémico - voriconazol, es un amplio espectro, triazol agente antifúngico y está indicado en adultos y niños de 2 años y por encima de la siguiente manera:el tratamiento de la aspergilosis invasiva;el tratamiento de la candidaemianon-pacientes neutropénicos;tratamiento de fluconazol resistente invasiva grave las infecciones por candida (incluyendo c. krusei);el tratamiento de graves de las infecciones fúngicas causadas por scedosporium spp. y fusarium spp. vfend debe ser administrado principalmente a pacientes con progresiva, posiblemente infecciones peligrosas para la vida. profilaxis de las infecciones fúngicas invasivas en alto riesgo de trasplante alogénico de trasplante de células madre hematopoyéticas (hsct) .

Unión Europea - español - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - antibacterianos para uso sistémico, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

Unión Europea - español - EMA (European Medicines Agency)

dechra regulatory b.v. - maropitant - tracto alimentario y metabolismo, otros antieméticos - cats; dogs - perros:para el tratamiento y la prevención de la náusea inducida por chemotherapyfor la prevención de los vómitos, excepto que la inducida por el movimiento sicknessfor el tratamiento de los vómitos, en combinación con otros de apoyo measuresfor la prevención de riesgo de náuseas y vómitos y la mejora en la recuperación de la anestesia general después de la utilización de la μ-opiáceo agonista de los receptores morphinecats:para la prevención de los vómitos y la reducción de las náuseas, excepto que la inducida por el movimiento sicknessfor el tratamiento de los vómitos, en combinación con otras medidas de apoyo.

Canadá - español - Ecolab

ecolab deutschland gmbh -